Sanofi with We Are ILL, Inc. Rings the Opening Bell
About This EventSanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the ...
Nasdaq1d
Sanofi with We Are ILL, Inc. Rings the Nasdaq Stock Market Opening Bell
Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square and around the globe. Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in ...
Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...
The Pharma Letter3h
Nurix expands licensing deal with Sanofi
US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...
Nasdaq8d
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...
Q1 Earnings Forecast for Sanofi Issued By Leerink Partnrs
Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Sanofi in a report released on ...
Nasdaq15d
Goldman Sachs Initiates Coverage of Sanofi - Depositary Receipt () (SNY) with Neutral Recommendation
Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with a Neutral recommendation. As of March 19, 2025, the average one-year ...
Nasdaq8d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...
Nasdaq9d
Sanofi's Tolebrutinib Under FDA Priority Review For Treating NrSPMS & Slowing Disability Progression
Sanofi noted that Tolebrutinib is currently ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...
Nasdaq8d
FDA Grants Fast Track Designation To Sanofi's MRNA Vaccine Candidate For Chlamydia Prevention
Sanofi said it is planning a phase 1/2 randomized ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...